How Does Johnson & Johnson Make its Money?
Johnson & Johnson is one of the world’s largest and most diversified healthcare companies. Following the August 2023 spinoff of Kenvue (its consumer health business, which included brands like Tylenol, Band-Aid, and Neutrogena), J&J now operates as a focused two-segment company: Innovative Medicine (pharmaceuticals) and MedTech (medical devices).
J&J’s pharmaceutical business develops treatments in immunology, oncology, neuroscience, cardiovascular, and infectious diseases. Its MedTech division makes surgical instruments, orthopedic implants, contact lenses, and interventional solutions used in hospitals worldwide. The company operates in virtually every country and has one of the largest R&D budgets in healthcare.
Johnson & Johnson (JNJ) Business Model
Johnson & Johnson operates in the healthcare sector. Below is a summary of Johnson & Johnson’s revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from Johnson & Johnson’s 2024 fiscal year filings with the SEC.
Johnson & Johnson Competitors
Johnson & Johnson’s key competitors and comparable public companies in the healthcare sector include Pfizer, Eli Lilly, and UnitedHealth Group. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Johnson & Johnson stacks up by comparing their revenue breakdown, margins, and growth metrics.
Johnson & Johnson Competitors
Johnson & Johnson’s key competitors and comparable public companies in the healthcare sector include Pfizer, Eli Lilly, and UnitedHealth Group. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Johnson & Johnson stacks up by comparing their revenue breakdown, margins, and growth metrics.
Johnson & Johnson Competitors
Johnson & Johnson’s key competitors and comparable public companies in the healthcare sector include Pfizer, Eli Lilly, and UnitedHealth Group. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Johnson & Johnson stacks up by comparing their revenue breakdown, margins, and growth metrics.
Johnson & Johnson Competitors
Johnson & Johnson’s key competitors and comparable public companies in the healthcare sector include Pfizer, Eli Lilly, and UnitedHealth Group. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Johnson & Johnson stacks up by comparing their revenue breakdown, margins, and growth metrics.
Johnson & Johnson Competitors
Johnson & Johnson’s key competitors and comparable public companies in the healthcare sector include Pfizer, Eli Lilly, and UnitedHealth Group. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Johnson & Johnson stacks up by comparing their revenue breakdown, margins, and growth metrics.
Johnson & Johnson Competitors
Johnson & Johnson’s key competitors and comparable public companies in the healthcare sector include Pfizer, Eli Lilly, and UnitedHealth Group. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Johnson & Johnson stacks up by comparing their revenue breakdown, margins, and growth metrics.
Johnson & Johnson Competitors
Johnson & Johnson’s key competitors and comparable public companies in the healthcare sector include Pfizer, Eli Lilly, and UnitedHealth Group. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Johnson & Johnson stacks up by comparing their revenue breakdown, margins, and growth metrics.
Johnson & Johnson Competitors
Johnson & Johnson’s key competitors and comparable public companies in the healthcare sector include Pfizer, Eli Lilly, and UnitedHealth Group. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Johnson & Johnson stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Innovative Medicine (Pharma) | $57.1B | $54.8B | +4.2% |
| MedTech (Devices) | $31.2B | $30.4B | +2.6% |
| Total Revenue | $88.8B | $85.2B | +4.2% |
Innovative Medicine — 64% of Revenue
J&J’s largest and most profitable segment. Key therapeutic areas and flagship products include:
- Immunology — Stelara ($10.4B, treating psoriasis, Crohn’s disease, and ulcerative colitis) and Tremfya ($4.1B, psoriasis and psoriatic arthritis). Stelara faces biosimilar competition beginning in 2025, making it the biggest patent cliff challenge.
- Oncology — Darzalex ($10.8B, multiple myeloma — one of the top-selling cancer drugs globally), Erleada ($2.5B, prostate cancer), and Carvykti (CAR-T cell therapy for multiple myeloma, growing rapidly).
- Neuroscience — Spravato (treatment-resistant depression) and a pipeline targeting Alzheimer’s and other neurological conditions.
- Cardiovascular — Xarelto (blood thinner, declining as it loses exclusivity) and a growing pulmonary hypertension portfolio.
MedTech — 36% of Revenue
A broad portfolio of medical devices and surgical products:
- Orthopedics — Hip and knee replacements, spine, sports medicine, and trauma. J&J’s DePuy Synthes is one of the top orthopedic companies globally.
- Surgery — Surgical instruments, wound closure products, energy devices. Includes the Ottava robotic surgery platform under development.
- Vision — Acuvue contact lenses and intraocular lenses.
- Interventional Solutions — Electrophysiology (Biosense Webster) for treating heart rhythm disorders, growing double digits.
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $88.8B | $85.2B |
| Cost of Products Sold | $28.4B | $27.8B |
| Gross Profit | $60.4B | $57.4B |
| Operating Expenses | $37.0B | $38.5B |
| Operating Income | $23.4B | $18.9B |
| Net Income | $14.1B | $13.3B |
Key Financial Metrics
- Gross Margin: 68.0% — High pharma-level margins reflecting J&J’s portfolio of patented medicines and premium medical devices.
- Operating Margin: 26.4% — Strong, with improvement in 2024 driven by reduced restructuring charges post-Kenvue spinoff and operating leverage.
- Revenue Growth: +4.2% — Solid organic growth anchored by Darzalex, Tremfya, Carvykti, and electrophysiology devices.
- R&D Spending: $14.9B — One of the largest R&D budgets in healthcare, supporting ~50 late-stage clinical programs.
- Dividend Yield: ~3.1% — J&J has increased its dividend for 62 consecutive years, making it a Dividend King and a core holding for income investors.
Is Johnson & Johnson Profitable?
Yes, Johnson & Johnson is profitable. The company reported net income of $14.1B on total revenue of $88.8B. With an operating margin of 26.4%, Johnson & Johnson demonstrates solid profitability for the healthcare sector. The gross margin of 68.0% reflects Johnson & Johnson’s pricing power and cost structure.
What to Watch
- Stelara biosimilar erosion — Stelara ($10.4B in revenue) begins facing biosimilar competition in 2025. This is J&J’s largest single patent cliff. The company must offset this with growth from Tremfya, Darzalex, and new launches.
- Carvykti/CAR-T scaling — Carvykti, J&J’s CAR-T cell therapy for multiple myeloma, is ramping quickly. Expanding manufacturing capacity and moving into earlier lines of therapy could make it a multi-billion dollar drug.
- Ottava robotic surgery — J&J’s answer to Intuitive Surgical’s da Vinci system. The Ottava platform is in development and could be a transformative MedTech growth driver if it gains regulatory approval and surgeon adoption.
- Talc litigation resolution — J&J has faced years of litigation over talc-based products. The company has attempted to resolve these claims through a settlement plan. Resolution would remove a major overhang on the stock.
- M&A strategy — J&J is actively acquiring to fill pipeline gaps. Recent deals have targeted cardiovascular, oncology, and retinal disease. The balance sheet (investment-grade rated) supports further acquisitions.
Johnson & Johnson (JNJ) Financial Summary
Johnson & Johnson (JNJ) is a healthcare company that generated $88.8B in total revenue in fiscal year 2024. Revenue grew +4.2% year-over-year. The company earned $14.1B in net income, making it profitable. For a deeper look at Johnson & Johnson’s revenue breakdown, business segments, and financial performance, review the detailed analysis above.